Literature DB >> 24071371

Inflammatory mediators from monocytes down-regulate cellular proliferation and enhance cytokines production in patients with polar clinical forms of Chagas disease.

Juliana Assis Silva Gomes1, Andreia Maria Molica2, Tatjana Souza Lima Keesen3, Maria José Ferreira Morato4, Fernanda Fortes de Araujo4, Rafaelle Christine Gomes Fares4, Jacqueline Araujo Fiuza4, Ana Thereza Chaves4, Vladimir Pinheiro2, Maria do Carmo Pereira Nunes5, Rodrigo Correa-Oliveira6, Manoel Otávio da Costa Rocha5.   

Abstract

Exposure to Trypanosoma cruzi parasites induces monocytes and macrophages to produce various endogenous mediators, including prostaglandins and cytokines. To clarify the involvement of monocytes as an important source of inflammatory mediators in Chagas disease patients, we evaluated PBMC before and after depletion of adherent cells (monocytes) from patients with indeterminate (IND) and cardiac (CARD) clinical forms and from non-infected individuals (NI). We demonstrated that after the partial depletion of adherent cells, production of PGE2 was slightly decreased in patients with Chagas disease. Inhibition of the cells by indomethacin increased the proliferation in PBMC cells from patients after antigen stimulation. Pro-inflammatory cytokines as IL-2 and IFN-γ also had a greater decrease after partial depletion of adherent cells in both clinical forms of Chagas disease. IL-10 and IL-5 levels were also reduced after partial depletion of adherent cells both in IND and CARD patients. In addition, we evaluated the APC potential of B cells and observed that the MHCII and CD80 molecules had an increased expression after partial depletion of most monocytes in all groups. Thus, inflammatory mediators produced by monocytes seem to be important to modulate immune responses in Chagas disease by regulating the processes of inflammation and antigen presentation.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CARD; CD; HLA-DR; IL; IND; MHC class II cell surface receptor; NI; PGE2; Prostagladin E2; TRYPO; cluster of differentiation; interleukin; non-infected individuals; patients with indeterminate clinical form of Chagas disease; patients with the cardiac clinical form of Chagas disease; tryposmastigotes antigen

Mesh:

Substances:

Year:  2013        PMID: 24071371     DOI: 10.1016/j.humimm.2013.09.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  11 in total

Review 1.  Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease.

Authors:  María Cecilia Albareda; Susana Adriana Laucella
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-05       Impact factor: 2.743

2.  Differential Activation of Human Monocytes and Lymphocytes by Distinct Strains of Trypanosoma cruzi.

Authors:  Luísa M D Magalhães; Agostinho Viana; Egler Chiari; Lúcia M C Galvão; Kenneth J Gollob; Walderez O Dutra
Journal:  PLoS Negl Trop Dis       Date:  2015-07-06

3.  Aspirin modulates innate inflammatory response and inhibits the entry of Trypanosoma cruzi in mouse peritoneal macrophages.

Authors:  Aparecida Donizette Malvezi; Rosiane Valeriano da Silva; Carolina Panis; Lucy Megumi Yamauchi; Maria Isabel Lovo-Martins; Nagela Ghabdan Zanluqui; Vera Lúcia Hideko Tatakihara; Luiz Vicente Rizzo; Waldiceu A Verri; Marli Cardoso Martins-Pinge; Sueli Fumie Yamada-Ogatta; Phileno Pinge-Filho
Journal:  Mediators Inflamm       Date:  2014-06-19       Impact factor: 4.711

4.  Differential Expression of Matrix Metalloproteinases 2, 9 and Cytokines by Neutrophils and Monocytes in the Clinical Forms of Chagas Disease.

Authors:  Nayara I Medeiros; Rafaelle C G Fares; Eliza P Franco; Giovane R Sousa; Rafael T Mattos; Ana T Chaves; Maria do Carmo P Nunes; Walderez O Dutra; Rodrigo Correa-Oliveira; Manoel O C Rocha; Juliana A S Gomes
Journal:  PLoS Negl Trop Dis       Date:  2017-01-24

5.  CD86 Expression by Monocytes Influences an Immunomodulatory Profile in Asymptomatic Patients with Chronic Chagas Disease.

Authors:  Bruna F Pinto; Nayara I Medeiros; Andrea Teixeira-Carvalho; Silvana M Eloi-Santos; Tereza C M Fontes-Cal; Débora A Rocha; Walderez O Dutra; Rodrigo Correa-Oliveira; Juliana A S Gomes
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

Review 6.  The Role of Co-Stimulatory Molecules in Chagas Disease.

Authors:  Bruna F Pinto; Nayara I Medeiros; Tereza C M Fontes-Cal; Isabela M Naziazeno; Rodrigo Correa-Oliveira; Walderez O Dutra; Juliana A S Gomes
Journal:  Cells       Date:  2018-11-07       Impact factor: 6.600

7.  Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.

Authors:  Néstor A Guerrero; Mercedes Camacho; Luis Vila; Miguel A Íñiguez; Carlos Chillón-Marinas; Henar Cuervo; Cristina Poveda; Manuel Fresno; Núria Gironès
Journal:  PLoS Negl Trop Dis       Date:  2015-08-25

8.  Immunoregulatory mechanisms in Chagas disease: modulation of apoptosis in T-cell mediated immune responses.

Authors:  Ana Thereza Chaves; Juliana de Assis Silva Gomes Estanislau; Jacqueline Araújo Fiuza; Andréa Teixeira Carvalho; Karine Silvestre Ferreira; Rafaelle Christine Gomes Fares; Pedro Henrique Gazzinelli Guimarães; Elaine Maria de Souza Fagundes; Maria José Morato; Ricardo Toshio Fujiwara; Manoel Otávio da Costa Rocha; Rodrigo Correa-Oliveira
Journal:  BMC Infect Dis       Date:  2016-04-30       Impact factor: 3.090

Review 9.  Inflammatory and Pro-resolving Lipids in Trypanosomatid Infections: A Key to Understanding Parasite Control.

Authors:  Rodrigo A López-Muñoz; Alfredo Molina-Berríos; Carolina Campos-Estrada; Patricio Abarca-Sanhueza; Luis Urrutia-Llancaqueo; Miguel Peña-Espinoza; Juan D Maya
Journal:  Front Microbiol       Date:  2018-08-21       Impact factor: 5.640

10.  Intermediate Monocytes and Cytokine Production Associated With Severe Forms of Chagas Disease.

Authors:  Sergio Gómez-Olarte; Natalia I Bolaños; Mariana Echeverry; Ayda N Rodríguez; Adriana Cuéllar; Concepción J Puerta; Alejandro Mariño; John M González
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.